The Endeavor stent, which Medtronic hopes can hold on to a respectable chunk of the $4 billion worldwide stent market, leads to more complications than rival devices and doesn’t reduce the need for future treatment, according to research presented at a conference yesterday. But the researchers cautioned that the study patients have only been followed for nine months so far, and Endeavor may have been placed into patients who were sicker to start with. Report